Trials / Completed
CompletedNCT03661632
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1/2 Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if BMS-986310 administered in combination with nivolumab, will demonstrate adequate safety and tolerability, as well as a favorable risk/benefit profile, to support further clinical testing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986310 | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2018-09-11
- Primary completion
- 2019-11-11
- Completion
- 2020-12-29
- First posted
- 2018-09-07
- Last updated
- 2021-11-08
Locations
7 sites across 3 countries: United States, Belgium, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03661632. Inclusion in this directory is not an endorsement.